Girish Mahajan (Editor)

Anthera Pharmaceuticals

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Type
  
Public

Industry
  
Pharmaceuticals

Founded
  
2004

Traded as
  
NASDAQ: ANTH

Website
  
Anthera.com

Anthera Pharmaceuticals httpswwwantheracomwpcontentuploads201603

Key people
  
Paul F. Truex (President and CEO)

Stock price
  
ANTH (NASDAQ) US$ 0.69 0.00 (+0.58%)24 Feb, 4:00 PM GMT-5 - Disclaimer

Headquarters
  
Hayward, California, United States

Profiles

LinkedIn

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. A-623 (Blisibimod) is Anthera’s leading drug candidate which is being developed for treatment of both systemic lupus erythematosus and IgA nephropathy.

Contents

Anthera pharmaceuticals inc anth stock chart technical analysis for 12 28 16


Blisibimod

  • Blisibimod is a selective peptibody antagonist of B-cell activating factor (BAFF). BAFF is critical to the development, maintenance and survival of B-cells, but is known to be up-regulated in autoimmune diseases. It is primarily expressed by macrophages, monocytes and dendritic cells. Blisibimod binds to BAFF and inhibits the interaction of BAFF with its receptors. Blisibimod is currently being evaluated in clinical trials in lupus [1] and [2] and IgA nephropathy [3].

    • Sollpura

    July 2014, Anthera acquired Sollpura (Liprotamase) from Eli Lilly and Company. Sollpura is an investigational pancreatic enzyme replacement therapy (PERT) that uses three biotechnology-derived digestive enzymes intended to treat patients with endocrine pancreatic insufficiency as a result of cystic fibrosis and other diseases.

    References

    Anthera Pharmaceuticals Wikipedia
    (Text) CC BY-SA